Physician, patient, and caregiver experience of different wet age-related macular degeneration anti-VEGF treatment regimens in Japan: a qualitative assessment
Tomohiro Iida,1 Keirei Ishii2 1Department of Ophthalmology, Tokyo Women’s Medical University, Tokyo, 2Health Economics and Outcomes Research, Bayer Yakuhin Ltd., Osaka, Japan Purpose: The purpose of this study was to monitor anti-vascular endothelial growth factor (anti-VEGF) tr...
Guardado en:
Autores principales: | Iida T, Ishii K |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ed93e2d55e3748ca8d0f4ada973f89e0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The emotional and physical impact of wet age-related macular degeneration: findings from the wAMD Patient and Caregiver Survey
por: Varano M, et al.
Publicado: (2016) -
Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group
por: Amoaku W, et al.
Publicado: (2018) -
Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration
por: Taipale C, et al.
Publicado: (2018) -
Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
por: Garweg JG
Publicado: (2019) -
Age, sex, and type of medication predict the effect of anti-VEGF treatment on central retinal thickness in wet age-related macular degeneration
por: Bek T, et al.
Publicado: (2018)